10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients greater than or equal to 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Trial Profile

10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients greater than or equal to 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2017 This trial has been completed in Bulgaria, as per European Clinical Trials Database record.
    • 14 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top